All In Biotech

Drug Trial Radar · NCT05722886

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

825

Planned (sponsor's estimate)

Start

Mar 1, 2023

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Cancer Research UKAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; Novartis Pharmaceuticals
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme. The DETERMINE trial will recruit adults, teenagers and children. If a drug is found to benefit a new patient group, the study team will work with the NHS and the Cancer Drugs Funds to see if these drugs can be available for patients in the future. This clinicaltrials.gov record refers to the Overall Trial Protocol (Master Screening Record), additional records will be added to clinicaltrials.gov for each treatment arm.

Conditions

  • Haematological Malignancy
  • Solid Tumour

Interventions

  • AlectinibDrug

    Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily. Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

  • AtezolizumabDrug

    Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days. Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days. Patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

  • EntrectinibDrug

    Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day). Paediatric patients with BSA \<1.51 m\^2 will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

  • Trastuzumab in combination with pertuzumabDrug

    The initial loading dose of trastuzumab is 8 mg/kg body weight followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days. The initial loading dose of pertuzumab is 840 mg followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive a dose of pertuzumab adjusted by body weight. Patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

  • Vemurafenib in combination with cobimetinibDrug

    Patients will receive vemurafenib at a dose of 960 mg (four tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle. Patients will receive cobimetinib at a dose of 60 mg (three tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break. Patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

  • CapmatinibDrug

    Patients will receive capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200 mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

  • Dabrafenib in combination with trametinibDrug

    Adult patients (≥18 years) will receive dabrafenib at a dose of 150 mg (two 75 mg tablets) twice daily (total daily dose 300 mg). Paediatric patients (1 to \<12 years) will receive dabrafenib dose adjusted by body weight as 10 mg dispersible tablets orally twice daily. Paediatric patients (≥12 years) and TYA patients (16 to \<18 years) will have the option to receive adult or paediatric dosing. Adult patients will receive trametinib at a daily dose of 2 mg (one 2 mg tablet) orally once daily (total daily dose 2 mg). Paediatric patients receive trametinib at a dose adjusted by body weight as 0.05 mg/m\^2 powder for oral solution twice daily. Paediatric patients (≥12 years) and TYA patients (16 to \<18 years) will have the option to receive adult or paediatric dosing. Each cycle of treatment will consist of 28 days. Patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients who consent to each arm.Time frame: Up to 5 years.

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Belfast City Hospital

    Belfast, United Kingdom · Recruiting

  • University Hospital Birmingham

    Birmingham, United Kingdom · Recruiting

  • Birmingham Children's Hospital

    Birmingham, United Kingdom · Not yet recruiting

  • Bristol Royal Hospital for Children

    Bristol, United Kingdom · Recruiting

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • Velindre Cancer Centre

    Cardiff, United Kingdom · Recruiting

  • Cardiff Children's Hospital

    Cardiff, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • The Beatson Hospital

    Glasgow, United Kingdom · Recruiting

  • Royal Hospital for Children Glasgow

    Glasgow, United Kingdom · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • Alder Hey Hospital

    Liverpool, United Kingdom · Recruiting

  • University College London Hospital

    London, United Kingdom · Recruiting

  • Guy's Hospital

    London, United Kingdom · Recruiting

  • Great Ormond Street Hospital

    London, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom · Recruiting

  • The Christie Hospital

    Manchester, United Kingdom · Recruiting

  • Clatterbridge Cancer Centre

    Metropolitan Borough of Wirral, United Kingdom · Recruiting

  • Great North Children's Hospital

    Newcastle, United Kingdom · Recruiting

  • Freeman Hospital

    Newcastle, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • John Radcliffe Hospital

    Oxford, United Kingdom · Recruiting

  • Weston Park Hospital

    Sheffield, United Kingdom · Recruiting

  • Sheffield's Children's Hospital

    Sheffield, United Kingdom · Recruiting

  • Southampton General Hospital

    Southampton, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.